Olmetec elderly dose restriction lifted

The licence for Olmetec (olmesartan medoxomil) has been extended.

The licence now includes the use of 40mg daily in the elderly. Previously elderly patients were restricted to a maximum dose of 20mg due to a lack of available clinical data in this patient population.

If up-titration to the maximum dose of 40mg is required, blood pressure should be closely monitored.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Reversal of benefits after novel migraine prophylactics stopped, study shows

Reversal of benefits after novel migraine prophylactics stopped, study shows

Findings from a recent study indicate a return to pre-treatment...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...